Oxervate and Eye infection bacterial - a phase IV clinical study of FDA data

Summary:

Eye infection bacterial is reported as a side effect among people who take Oxervate (cenegermin-bkbj), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Valacyclovir, and have Neurotrophic keratopathy.

The phase IV clinical study analyzes which people have Eye infection bacterial when taking Oxervate. It is created by eHealthMe based on reports of 7,219 people who have side effects when taking Oxervate from the FDA, and is updated regularly.

What is Oxervate?

Oxervate has active ingredients of cenegermin-bkbj. eHealthMe is studying from 7,219 Oxervate users. Check the latest studies of Oxervate.

What is Eye infection bacterial?

Eye infection bacterial is found to be associated with 73 drugs and 164 conditions by eHealthMe. Check the latest studies of Eye infection bacterial.

On Jul, 12, 2026

7,219 people reported to have side effects when taking Oxervate.
Among them, 25 people (0.35%) have Eye infection bacterial.

Could Oxervate cause Eye infection bacterial?

Among these 25 people:

How long have people been on Oxervate when they have Eye infection bacterial? *

What is the gender of people who have Eye infection bacterial when taking Oxervate? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Eye infection bacterial when taking Oxervate? *

What are other drugs people take besides Oxervate? *

What are other side effects people have besides Eye infection bacterial? *

Eye Pain: 11 people, 44.00%
Eye Swelling: 4 people, 16.00%
Eye Irritation: 4 people, 16.00%
Abnormal Sensation In Eye: 2 people, 8.00%
Photophobia (extreme sensitivity to light): 2 people, 8.00%
Ocular Hyperaemia (an abnormally large amount of blood in eye): 2 people, 8.00%
Lacrimation Increased: 2 people, 8.00%
Eye Discharge: 2 people, 8.00%
Chalazion (cyst in the eyelid): 1 person, 4.00%
Dacryocystitis (inflammation of the lacrimal sac causing obstruction of the tube draining tears into the nose): 1 person, 4.00%

What are the existing conditions these people have? *

Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 23 people, 92.00%
Ulcerative Keratitis (ulcerative inflammation of the cornea): 5 people, 20.00%
Hypoaesthesia Eye (reduced sense of touch or sensation on eyes): 5 people, 20.00%
Dry Eyes (lack of adequate tears): 3 people, 12.00%
Stress And Anxiety: 2 people, 8.00%
Iridocyclitis (inflammation of the iris and ciliary body of the eye): 2 people, 8.00%
High Blood Pressure: 2 people, 8.00%
Corneal Abrasion (loss of the surface of cornea): 2 people, 8.00%
Uveitis (inflammation of the uvea): 1 person, 4.00%
Intraocular Pressure Increased: 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Oxervate and have Eye infection bacterial?

- Check whether Eye infection bacterial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Oxervate:

Oxervate (7,219 reports)

Browse all side effects of Oxervate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eye infection bacterial:

Eye infection bacterial (74 drugs)

Browse all the conditions that are associated with Eye infection bacterial:

Eye infection bacterial (164 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cenegermin-bkbj (the active ingredients of Oxervate) and Oxervate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.